Literature DB >> 2830402

Subclasses of cyclic AMP phosphodiesterase in cardiac muscle.

R E Weishaar1, D C Kobylarz-Singer, H R Kaplan.   

Abstract

Canine and guinea-pig left ventricular muscle contains multiple molecular forms of phosphodiesterase (PDE) which vary according to substrate specificity, stimulation by calmodulin and response to various selective and nonselective phosphodiesterase inhibitors. Both species possess a cyclic AMP-specific form of phosphodiesterase (PDE III). In the dog, both soluble and particulate forms of PDE III are present. The particulate form of PDE III is potently inhibited by cyclic GMP and the selective PDE III inhibitors imazodan (CI-914) and cilostamide, but is only weakly inhibited by the selective PDE III inhibitors Ro 20-1724 and rolipram. In contrast, the soluble form of PDE III in canine left ventricle is only weakly inhibited by cyclic GMP, imazodan and cilostamide, but is potently inhibited by Ro 20-1724 and rolipram. Guinea-pig left ventricle contains only one subclass of PDE III, which is potently inhibited by cyclic GMP, imazodan and cilostamide, but not by Ro 20-1724 or rolipram. However, whereas the imazodan-sensitive subclass of PDE III is a particulate enzyme in the canine left ventricle, in the guinea-pig this subclass of PDE III is a soluble enzyme. Both soluble and particulate PDE III's are (i) insensitive to calmodulin; (ii) possess comparable Km and Vmax values for hydrolysis of cyclic AMP; (iii) are equally inhibited by the nonselective PDE inhibitor theophylline, and (iv) are eluted from DEAE-cellulose anion-exchange resin by comparable concentrations of sodium acetate. The demonstration of distinct subclasses of the cyclic AMP-specific phosphodiesterase (PDE III) in canine left ventricular muscle associated with different domains of the cell suggests compartmentation of cyclic AMP. In addition, the observation that the imazodan-sensitive form of PDE III is a particulate enzyme in canine left ventricle and a soluble enzyme in guinea-pig left ventricle may explain the species differences which exist regarding the positive inotropic response to imazodan in these two species.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2830402     DOI: 10.1016/s0022-2828(87)80574-6

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study.

Authors:  L Okruhlicová; N Tribulová; J Styk; A Eckly; C Lugnier; J Slezk
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  Potentiation by cyclic GMP of beta-adrenergic effect on Ca2+ current in guinea-pig ventricular cells.

Authors:  K Ono; W Trautwein
Journal:  J Physiol       Date:  1991-11       Impact factor: 5.182

Review 3.  New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.

Authors:  R E Weishaar; D Kobylarz-Singer; B A Klinkefus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 4.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

5.  Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.

Authors:  I Verde; G Vandecasteele; F Lezoualc'h; R Fischmeister
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices.

Authors:  R A Challiss; C D Nicholson
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

7.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.

Authors:  J Schneider; E Beck; C Heers; C Conrad; D de Chaffoy de Courcelles; B Wilffert; T Peters
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

9.  Synergistic action of cyclic GMP on catecholamine-induced chloride current in guinea-pig ventricular cells.

Authors:  K Ono; F M Tareen; A Yoshida; A Noma
Journal:  J Physiol       Date:  1992       Impact factor: 5.182

10.  Long lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities.

Authors:  G Borchert; S Bartel; I Beyerdörfer; I Küttner; L Szekeres; E G Krause
Journal:  Mol Cell Biochem       Date:  1994-03-16       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.